List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

Displaying 51 - 60 of 5001 results
  1. Identification of Brucella canis seroreactive antigens using a pan Brucella proteome microarray

    SBC: ImmPORT Therapeutics Inc dba Antigen Discovery Inc            Topic: ODCDC

    Brucellosis is a worldwide re emerging bacterial zoonosis that can affect a range of different mammals including cattlesheepgoatsswinedogsand importantly humansEvery yearmore thanpeople worldwide are infected with virulent strains of Brucellagram negative coccobacillus from animal hostsEstimates have been made suggesting the true incidence may be much higherFour Brucella species that have animal h ...

    SBIR Phase I 2018 Department of Health and Human Services
  2. Topic 377: Bridging the Guideline Implementation Gap: Clinical Decision Support to Improve Cancer Symptom Management

    SBC: Cognitive Medical Systems, Inc.            Topic: NCI

    Advances in clinical research have yielded many evidence-based guidelines to help clinicians provide the right care for the right patient at the right time; however, studies suggest that nearly half the time, that care does not reach the patient. Clinical decision support (CDS) is an information technology-enabled method to identify missed opportunities and optimize care. This proposal seeks to sy ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Topic 371: Validation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation

    SBC: Riptide Bioscience, Inc.            Topic: NCI

    Radiotherapy, a key anticancer therapy, acts not only by killing cancer cells, but also by activating the body's immune system to attack the remaining cancer cells. However, the immune-stimulating effect is weakened by the tumor's capacity to reprogram immune cells, particularly macrophages, so that they instead actively promote tumor growth. RP-185 (Riptide Biosciences, Vallejo, CA),an engineered ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Topic 378: Symptomatic Toxicity Mobile Monitor (SympTMM)

    SBC: Vivonics, Inc.            Topic: NCI

    The goal of this NIH Phase I SBIR proposal is to develop and validate a new method to monitor the symptomatic toxicities and health-related quality of life of cancer patients who are undergoing and have undergone radiation therapy during the course of their treatment. The proposal is built around expertise in mobile application development (Vivonics Inc.) and radiation oncology (Dr. TJ Fitzgerald ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Topic 378: PRORAD- A Mobile Application for Patient Related Outcomes of Radiotherapy

    SBC: Charles River Analytics, Inc.            Topic: NCI

    Cancer patients receiving radiation therapy experience toxic side effects of the radiation, and sensitivity to radiation is variable across both patients and tumors, and is poorly understood. This Phase I SBIR project aims to design and demonstrate the feasibility of a Patient Reported Outcome mobile application for surveillance of RADiotherapy toxicity (PRORAD) that integrates NIH's Patient Repor ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Topic 379: DigiBioMarC: Digital BioMarkers for Clinical Impact- Moonshot

    SBC: Medable Inc.            Topic: NCI

    The overall objective of this Fast-Track SBIR contract project is to develop DigiBioMarCTM (Digital BioMarkers for Clinical Impact), a scalable and flexible cloud-based platform to capture and analyze wearable, implantable, or external device data. This platform also provides an informatics tool for automated data aggregation, integration, and machine learning algorithms. It is based on the scalab ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Topic 374: Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention

    SBC: TheraNano LLC            Topic: NCI

    Here we propose to study two injectable formulations that provide different delivery routes for Talazoparib, potent PAPR inhibitor: An implant, InCeT-Talazoparib, which can be injected directly in the tumor where it will act as a sustained release depot of Talazoparib over a prolonged period of approximately 30 days. It delivers 100% of the drug to the tumor site with almost no systemic toxicity. ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Topic 343- Cognitive Assessment and Monitoring Platform For Integrative Research (CAMPFIRE II)

    SBC: Charles River Analytics, Inc.            Topic: NCI

    Cancer survivors commonly report cognitive impairments following chemotherapy. With a growing number of cancer survivors comes an increased urgency to better understand the precise etiology and prevalence of cognitive changes associated with cancer and cancer treatment. This pursuit is impeded by a lack of assessment tools that can accurately detect the full scope of cognitive deficits. To address ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 363- CONNECTING CANCER CAREGIVERS TO CARE TEAMS: DIGITAL PLATFORMS TO SUPPORT INFORMAL CANCER CAREGIVING

    SBC: Medable Inc.            Topic: NCI

    TOGETHER is a mobile application on a smart software system that informal caregivers will use to develop and implement home-based care for cancer survivors. It will help alleviate the cancer caregiving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan. The goal of this Fast-Track project is to develop and validate a final TOGETHER ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Topic 345: RadTox- Measuring Radiation Toxicity using Circulating DNA

    SBC: DiaCarta, Inc.            Topic: NCI

    The QuantiDNA RadTox System is a unique, patented technology that measures tissue damage shortly following injury using cell-free DNA from a drop of blood. Premised on murine and primate studies showing circulating DNA is logarithmically increased with whole-body radiation dose, RadTox has the potential to overcome many of the species-specific challenges faced by biomarker panels. The phase I SBIR ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government